傷寒疫苗市場：依疫苗類型、給藥途徑及地區分類

預計到2026年，傷寒疫苗市場規模為5.586億美元，到2033年將達到12.44億美元。預計從2026年到2033年，其複合年成長率將達到12.2%。

傷寒是由傷寒沙門氏菌引起的細菌感染疾病，其症狀包括持續發燒、頭痛、噁心、食慾不振、便秘或腹瀉。細菌通常透過受污染的食物或水經口進入人體，穿透腸壁，並在淋巴組織中繁殖。隨後，細菌進入血液，引起菌血症。飲用受污染的水或食用受污染的水清洗過的食物的人有感染傷寒的風險。傷寒主要發生在衛生條件不佳、缺乏乾淨飲用水的地區。傷寒疫苗是生物製藥，可提供免疫力，保護個體免受傷寒感染。

目前，世界衛生組織（世衛組織）建議的傷寒疫苗有三種，分別是：

• 注射型傷寒結合疫苗（TCV）：該疫苗含有與破傷風類毒素蛋白結合的 Vi 多醣抗原，核准用於 6 個月及以上的兒童和 45 歲以下的成人。
• 這是一種基於純化 Vi 抗原的非結合多醣疫苗（稱為 Vi-PS 疫苗），適用於 2 歲及以上人群。
• 適用於 6 歲及以上族群的口服減毒活疫苗 Ty21a 膠囊劑。

市場動態

預計在預測期內，各國政府和其他組織加大力度提高民眾對傷寒疫苗的認知，以及新疫苗的普及，將推動傷寒疫苗市場成長。例如，2019年2月，全球疫苗免疫聯盟（Gavi）與世界衛生組織、美國疾病管制與預防中心以及辛巴威衛生署合作，發起了宣傳活動。 Gavi是官民合作關係，致力於幫助全球一半的兒童接種疫苗，並預防一些世界上最致命的疾病。這項宣傳活動的目標是在津巴布韋首都的九個郊區為32.5萬人接種新型傷寒結合疫苗（TCV）。全球至少有1,240萬名兒童被列為「零劑量」兒童，他們生活在缺乏基本服務（包括醫療保健）的貧困社區。

本報告的主要特點

• 本報告指出了各個細分市場的潛在商機，並概述了該市場中一系列有吸引力的投資提案。
• 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
• 本節根據以下參數介紹全球傷寒疫苗市場主要企業的概況：公司概況、產品系列、主要亮點、財務績效和策略。
• 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
• 《全球傷寒疫苗市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 相關人員可以透過分析全球傷寒疫苗市場中使用的各種策略矩陣來促進決策。

目錄

第1章：分析目標與假設

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 阻礙因素
  • 市場機遇
• 影響分析
• 新產品上市及核准
• PEST分析
• 品牌知名度策略
• 救贖方案
• 供不應求
• 臨床試驗分析
• 蛇咬傷事件高發生的國家
• 市場准入的挑戰

第4章：全球傷寒疫苗市場：依疫苗類型分類（2026-2033 年）

• 活病毒疫苗
• 莢膜多醣疫苗
• 結合疫苗
• 其他

第5章：全球傷寒疫苗市場：依給藥途徑分類（2026-2033 年）

• 口服
• 注射

第6章：全球傷寒疫苗市場：依地區分類（2026-2033年）

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 亞太其他地區
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第7章 競爭情勢

• 熱圖分析
• 公司簡介
  • GlaxoSmithKline Plc.
  • Sanofi SA
  • Bharat Biotech
  • Bio-Med Pvt. Ltd.
  • PT Bio Farma
  • PaxVax, Inc.
  • Shanghai Institute of Biological Products Co., Ltd.
  • Prokarium

第8章

• 參考
• 分析方法

Typhoid Fever Vaccines Market is estimated to be valued at USD 558.6 Mn in 2026 and is expected to reach USD 1,244.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 12.2% from 2026 to 2033.

Typhoid fever is a bacterial infection caused by Salmonella typhi, which causes symptoms such as prolonged fever, headache, nausea, loss of appetite, and constipation or sometimes diarrhea. The bacterium usually enters the body through the mouth by the ingestion of contaminated food or water, penetrates the intestinal wall, and multiplies in lymphoid tissue. It then enters the bloodstream and causes bacteremia. People who drink contaminated water or eat food washed in contaminated water can develop typhoid fever. Typhoid fever is majorly caused in area with poor sanitation and lack of clean drinking water. Typhoid fever vaccines are the biological formulations, which provide immunity and protect an individual against typhoid fever.

Currently there are three typhoid vaccines recommended by the World Health organization (WHO) for use which include:

• Injectable typhoid conjugate vaccine (TCV), consisting of Vi polysaccharide antigen linked to tetanus toxoid protein licensed for children from 6 months of age and adults up to 45 years of age
• Injectable unconjugated polysaccharide vaccine based on the purified Vi antigen (known as Vi-PS vaccine) for persons aged two years and above, and
• Oral live attenuated Ty21a vaccine in capsule formulation for those over six years of age

Market Dynamics

Increasing initiatives by governments and various other organizations to increase awareness about typhoid vaccine and rising access of new vaccines is expected to drive the typhoid fever vaccines market growth during forecast period. For instance, in February 2019, Gavi, the Vaccine Alliance in partnership with WHO, Center for Disease Control and Prevention and Zimbabwe's Ministry of Health launched a campaign to tackle typhoid outbreak in Zimbabwe. Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world's children against some of the world's deadliest diseases. The campaign aims to vaccinate 325,000 people in nine suburbs of Zimbabwe's capital with new typhoid conjugate vaccine (TCV). At least 12.4 million children worldwide are categorized as 'zero-dose', living in missed communities that cannot access many essential services, including health care.

Key features of the study

• This report provides an in-depth analysis of the global typhoid fever vaccines market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global typhoid fever vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc. Shanghai Institute of Biological Products Co., Ltd., and Prokarium.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global typhoid fever vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global typhoid fever vaccines market

Market Segmentation

• By Vaccine Type
  • Live Attenuated Vaccine
  • Capsular Polysaccharide Vaccines
  • Conjugate Vaccine
  • Others
• By Route of Administration
  • Oral
  • Parenteral
• By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa
• Key Players
  • GlaxoSmithKline Plc.
  • Sanofi SA
  • Bharat Biotech
  • Bio-Med Pvt. Ltd.
  • PT Bio Farma
  • PaxVax, Inc.
  • Shanghai Institute of Biological Products Co., Ltd.
  • Prokarium

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Vaccine Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Novel Product Launch/Approval
• PEST Analysis
• Awareness Strategy
• Reimbursement Scenario
• Typhoid Fever Vaccines Shortage
• Clinical Trial Analysis
• Countries with High Number of Incidents of Snake Bites
• Market Entry Challenges

4. Global Typhoid Fever Vaccines Market, By Vaccine Type, 2026 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Live Attenuated Vaccine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
• Capsular Polysaccharide Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
• Conjugate Vaccine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)

5. Global Typhoid Fever Vaccines Market, By Route of Administration, 2026 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
• Parental
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)

6. Global Typhoid Fever Vaccines Market, By Region, 2026 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2026-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

• Heat Map Analysis
• Company Profiles
  • GlaxoSmithKline Plc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Sanofi SA
    • Company Introduction
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bharat Biotech
    • Company Introduction
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bio-Med Pvt. Ltd.
    • Company Introduction
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • PT Bio Farma
    • Company Introduction
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • PaxVax, Inc.
    • Company Introduction
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Shanghai Institute of Biological Products Co., Ltd.
    • Company Introduction
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Prokarium
    • Company Introduction
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

• References
• Research Methodology
• About Us and Sales Contact